Rapid loss of response after withdrawal of treatment with azacitidine: a case series in patients with higher‐risk myelodysplastic syndromes or chronic myelomonocytic leukemia
- 21 January 2013
- journal article
- case report
- Published by Wiley in European Journal of Haematology
- Vol. 90 (4) , 345-348
Abstract
In patients with myelodysplastic syndromes (MDS), the likelihood of having a sustained response to azacitidine is increased by maximizing treatment duration. This is important as prognosis postrelapse is poor. There is also the concern that early termination of treatment may result in rapid disease progression. We reviewed outcomes in 13 patients who discontinued azacitidine (decitabine in one patient) while still responding to the treatment. Most patients rapidly relapsed; median time to progression was 5.4 months. Reasons for treatment discontinuation included comorbidities, infections, and patient choice. These findings illustrate the risk of prematurely terminating azacitidine therapy in MDS.Keywords
This publication has 14 references indexed in Scilit:
- Outcome of High-Risk Myelodysplastic Syndrome After Azacitidine Treatment FailureJournal of Clinical Oncology, 2011
- Low-Dose Decitabine Versus Best Supportive Care in Elderly Patients With Intermediate- or High-Risk Myelodysplastic Syndrome (MDS) Ineligible for Intensive Chemotherapy: Final Results of the Randomized Phase III Study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study GroupJournal of Clinical Oncology, 2011
- Continued azacitidine therapy beyond time of first response improves quality of response in patients with higher‐risk myelodysplastic syndromesCancer, 2011
- Risk stratification based on both disease status and extra-hematologic comorbidities in patients with myelodysplastic syndromeHaematologica, 2010
- Effects of azacitidine compared with conventional care regimens in elderly (≥75 years) patients with higher-risk myelodysplastic syndromesCritical Reviews in Oncology/Hematology, 2010
- Outcome of patients with myelodysplastic syndrome after failure of decitabine therapyCancer, 2010
- Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III studyThe Lancet Oncology, 2009
- Azacytidine causes complex DNA methylation responses in myeloid leukemiaMolecular Cancer Therapeutics, 2008
- Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasiaBlood, 2006
- Superiority of prolonged low‐dose azanucleoside administration?Cancer, 2006